Impact of Early Treatment with High-Dose Intravenous Immunoglobulin on Incidence of Kawasaki Disease Complications in Iranian Children
-
Alireza Karimi Yazdi
,
Parvin Akbariasbagh
,
Yahya Aghighi
,
Seyyed Reza Raeeskarami
,
Khadije Toomaj
,
Sahar Heidari
,
Shahnaz Alamdari
,
Leyla Sahebi
Abstract
Objective: Kawasaki disease (KD) occurs in five-year-old or younger children. This study aimed to evaluate the impact of high-dose intravenous immunoglobulin plus acetylsalicylic acid therapy on the prevention and treatment of coronary artery lesions and to evaluate the impact of high-dose acetylsalicylic acid (ASA) on the hearing of the patients.
Materials and methods: In this retrospective cohort study, 31 patients with KD were followed from January 2012 to December 2015. The clinical, para-clinical, color Doppler echocardiogram and audiometry results were evaluated.
Results: Overall, seven cases (22.6%) developed coronary artery aneurysm (CAA) in the acute phase of the disease, of whom only two still had CAA at the end of the treatment (6%). One of the five children with CAA recovery had a delay in the onset of treatment and one of two patients with persistent CAA at the end of treatment was admitted within the first 10 days. There was no evidence-based abnormal liver biochemical test. None of the patients developed sensorineural hearing loss (SNHL) on audiometry tests conducted before and after treatment.
Conclusion: Recovery of coronary artery lesions was 71.43% after 28 days of the onset of treatment. The distribution of coronary artery aneurysm was not different in terms of the time of the treatment initiation (P-Value = 0.371). None of the children had a sensorineural hearing loss (SNHL) 48 hours and 4 weeks after treatment.
1. Burns JC, Glodé MP. Kawasaki syndrome. Lancet 2004; 364: 533-44.
2. Smith KA, Yunker WK. Kawasaki disease is associated with sensorineural hearing loss: a systematic review. Int J Pediatr Otorhinolaryngol 2014; 78: 1216-20.
3. Luca NJ, Yeung RS. Epidemiology and management of Kawasaki disease. Drugs 2012; 72: 1029–38.
4. Zhu BH, Lv HT, Sun L, Zhang JM, Cao L, Jia HL, et al. A meta-analysis on the effect of corticosteroid therapy in Kawasaki disease.Eur J Pediatr 2012; 171: 571-8.
5. Takagi K, Umezawa T, Saji T, Morooka K, Matsuo N. Meningoencephalitis in Kawasaki disease. No To Hattatsu 1990; 22: 429-35.
6. Terasawa K, Ichinose E, Matsuishi T, Kato H. Neurological complications in Kawasaki disease. Brain Dev 1983; 5: 371-4.
7. Knott PD, Orloff LA, Harris JP, Novak RE, Burns JC; Kawasaki Disease Multicenter Hearing Loss Study Group. Sensorineural hearing loss and Kawasaki disease: a prospective study. Am J Otolaryngol 2001; 22: 343-8.
8. Silva CH, Roscoe IC, Fernandes KP, Novaes RM, Lazari CS. Sensorineural hearing loss associated to Kawasaki Disease. J Pediatr (Rio J) 2002; 78: 71-4.
9. Park SY, Kim YH, Kim YH, Hyun MC, LeeYH. Sensorineural hearing loss in patients with Kawasaki. Korean J Pediatr 2015; 58: 434-9.
10. Tse SM, Silverman ED, McCrindle BW, Yeung RS. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease. J Pediatr 2002; 140: 450-5.
11. Kordidarian R, Kazemi A, Nikyar A, Torfeh Nejad M. Assessing Kawasaki disease in children at Alzahra hospital (1995-1999). Journal of Inflammatory Diseases (The Journal of Qazvin University of Medical Sciences) 2008; 11: 42-7. [in Persian]
12. Du ZD, Di Z, Du JB, Lu S, Yi JM, Hou AC, et al. Comparison of efficacy among early, conventional and late intravenous gamma globulin treatment of Kawasaki disease. Zhonghua Yi Xue Za Zhi 2009; 89: 1841-3.
13. Sundel RP, Cleveland SS, Beiser AS, Newburger JW, McGill T, Baker AL, et al. Audiologic profiles of children with Kawasaki disease. Am J Otol 1992; 13: 512-5.
14. Novo A, Pinto S, Prior AC, Alvares S, Soares T, Guedes M. Kawasaki disease and sensorineural hearing loss: a (un) expected complication. Eur J Pediatr 2012; 171: 851-4.
15. Magalhães CM, Magalhães Alves NR, Oliveira KM, Silva IM, Gandolfi L, Pratesi R. Sensorineural hearing
loss: an underdiagnosed complication of Kawasaki disease. J Clin Rheumatol 2010; 16: 322-5.
16. Kara A, Beşbaş N, Tezer H, Karagöz T, Devrim I, Unal OF. Reversible sensorineural hearing loss in a girl with Kawasaki disease. Turk J Pediatr 2007; 49: 431-3.
17. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004; 110: 2747-71.
18. Van Stijn-Bringas Dimitriades D, Planken N, Kuipers I, Kuijpers T. CT Angiography or Cardiac MRI for Detection of Coronary Artery Aneurysms in Kawasaki Disease. Front Pediatr 2021; 9: 630462.
19. Schlauch RS, Nelson P. Puretone evaluation. In: Katz J, Medwetsky L, Burkard R, Hood LJ, editors. Handbook of Clinical Audiology. 6th ed. Baltimore: Lippincott Williams & Wilkins; 2009: 30-49.
20. Kayiran SM, Dindar A, Gurakan B. An evaluation of children with Kawasaki disease in Istanbul: a retrospective follow-up study Clinics (Sao Paulo) 2010; 65: 1261-5.
21. Gardner-Medwin JM, Dolezalova P, Cummins C, Southwood TR. Incidence of Henoch-Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet 2002; 360: 1197-202.
22. Saffar MJ, Reshidighader F. Kawasaki disease in East Mazanda¬ran Islamic Republic of Iran, 1997-2002. Eastern Mediterranean Health Journal 2005; 11: 28–35.
23. Emami Moghadam A. Hosseinzadeh NM. Study of Clinical and Laboratory Findings in Children with Kawasaki Disease Hospitalized at Ahvaz Abuzar and Golestan Hospitals. Jundishapur Scientific Medical Journal 2011; 9: 543-51.
24. Pierre R, Sue-Ho R, Watson D. Kawasaki syndrome in Jamaica. Pe¬diatr Infect Dis J 2000; 19: 539–43.
25. Du ZD, Zhang T, Liang L, Meng X, Li T, Kawasaki T, et al. Epidemio¬logic picture of Kawasaki disease in Beijing from 1995 through 1999. Pediatr Infect Dis
J 2002; 21: 103–7.
26. Park YW, Han JW, Park IS, Kim CH, Cha SH, Ma JS, et al. Kawasaki disease in Korea, 2003-2005. Pediatr Infect Dis J 2007; 26: 821–3.
27. Gorczyca D, Postępski J, Olesińska E, Lubieniecka M, Lachór-Motyka I, Opoka-Winiarska V, Gruenpeter A. The clinical profile of Kawasaki disease of children from three Polishcenters: a retrospective study.
Rheumatol Int 2014; 34: 875-80.
28. Moradinezhad MH, Kiani A. Kawasaki Disease in 159 Iranian Children. IRANIAN journal of pediatrics 2007; 17: 241-6.
29. Lee BW, Tay JS, Yip WC, Yap HK, Chan KY, Low PS. Kawasaki syn¬drome in Chinese children. Ann Trop Paediatr 1989; 9: 147–51.
30. Schiller B, Fasth A, Bjorkhem G, Elinder G. Kawasaki disease in Sweden: incidence and clinical features. Acta Paediatr 1995; 84: 769–74.
31. Sadeghi P, Izadi A, Mojtahedi SY, Khedmat L, Jafari M, Afshin A, et al. A 10-year cross-sectional retrospective study on Kawasaki disease in Iranian children: incidence, clinical manifestations, complications, and treatment patterns. BMC Infect Dis 2021; 21: 368.
32. Burns JC, Cayan DR, Tong G, Bainto EV. Turner CL, Shike H, et al. Seasonality and Temporal Clustering of Kawasaki Syndrome. Epidemiology 2005 16: 220–5.
33. Chang RK. Hospitalizations for Kawasaki disease among chil¬dren in the United States, 1988-1997. Pediatrics 2002; 109: e87.
34. Clausen H, Howarth C, Giardini A. Kawasaki disease: always straight to the heart? BMJ Case Rep 2012; 2012: bcr2012006505.
35. Rowley AH, Shulman ST. New developments in the search for the etiologic agent of Kawasaki disease. Curr Opin Pediatr 2007; 19: 71-4.
36. Bal AK, Prasad D, Umali Pamintuan MA, Mammen-Prasad E, Petrova A. Timing of intravenous immunoglobulin treatment and risk of coronary artery abnormalities in children with Kawasaki disease. Pediatr Neonatol 2014; 55: 387-92.
37. Brien JA. Ototoxicity associated with salicylates: a brief review. Drug Saf 1993; 9: 143-8.
38. Shulman ST, Rowley AH. Advances in Kawasaki disease. Eur J Pediatr 2004; 163: 285-91.
39. Day RO, Graham GG, Bieri D, Brown M, Cairns D, Harris G, et al. Concentration-response relationships for salicylate-induced ototoxicity in normal volunteers. Br J Clin Pharmacol 1989; 28: 695-702.
2. Smith KA, Yunker WK. Kawasaki disease is associated with sensorineural hearing loss: a systematic review. Int J Pediatr Otorhinolaryngol 2014; 78: 1216-20.
3. Luca NJ, Yeung RS. Epidemiology and management of Kawasaki disease. Drugs 2012; 72: 1029–38.
4. Zhu BH, Lv HT, Sun L, Zhang JM, Cao L, Jia HL, et al. A meta-analysis on the effect of corticosteroid therapy in Kawasaki disease.Eur J Pediatr 2012; 171: 571-8.
5. Takagi K, Umezawa T, Saji T, Morooka K, Matsuo N. Meningoencephalitis in Kawasaki disease. No To Hattatsu 1990; 22: 429-35.
6. Terasawa K, Ichinose E, Matsuishi T, Kato H. Neurological complications in Kawasaki disease. Brain Dev 1983; 5: 371-4.
7. Knott PD, Orloff LA, Harris JP, Novak RE, Burns JC; Kawasaki Disease Multicenter Hearing Loss Study Group. Sensorineural hearing loss and Kawasaki disease: a prospective study. Am J Otolaryngol 2001; 22: 343-8.
8. Silva CH, Roscoe IC, Fernandes KP, Novaes RM, Lazari CS. Sensorineural hearing loss associated to Kawasaki Disease. J Pediatr (Rio J) 2002; 78: 71-4.
9. Park SY, Kim YH, Kim YH, Hyun MC, LeeYH. Sensorineural hearing loss in patients with Kawasaki. Korean J Pediatr 2015; 58: 434-9.
10. Tse SM, Silverman ED, McCrindle BW, Yeung RS. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease. J Pediatr 2002; 140: 450-5.
11. Kordidarian R, Kazemi A, Nikyar A, Torfeh Nejad M. Assessing Kawasaki disease in children at Alzahra hospital (1995-1999). Journal of Inflammatory Diseases (The Journal of Qazvin University of Medical Sciences) 2008; 11: 42-7. [in Persian]
12. Du ZD, Di Z, Du JB, Lu S, Yi JM, Hou AC, et al. Comparison of efficacy among early, conventional and late intravenous gamma globulin treatment of Kawasaki disease. Zhonghua Yi Xue Za Zhi 2009; 89: 1841-3.
13. Sundel RP, Cleveland SS, Beiser AS, Newburger JW, McGill T, Baker AL, et al. Audiologic profiles of children with Kawasaki disease. Am J Otol 1992; 13: 512-5.
14. Novo A, Pinto S, Prior AC, Alvares S, Soares T, Guedes M. Kawasaki disease and sensorineural hearing loss: a (un) expected complication. Eur J Pediatr 2012; 171: 851-4.
15. Magalhães CM, Magalhães Alves NR, Oliveira KM, Silva IM, Gandolfi L, Pratesi R. Sensorineural hearing
loss: an underdiagnosed complication of Kawasaki disease. J Clin Rheumatol 2010; 16: 322-5.
16. Kara A, Beşbaş N, Tezer H, Karagöz T, Devrim I, Unal OF. Reversible sensorineural hearing loss in a girl with Kawasaki disease. Turk J Pediatr 2007; 49: 431-3.
17. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004; 110: 2747-71.
18. Van Stijn-Bringas Dimitriades D, Planken N, Kuipers I, Kuijpers T. CT Angiography or Cardiac MRI for Detection of Coronary Artery Aneurysms in Kawasaki Disease. Front Pediatr 2021; 9: 630462.
19. Schlauch RS, Nelson P. Puretone evaluation. In: Katz J, Medwetsky L, Burkard R, Hood LJ, editors. Handbook of Clinical Audiology. 6th ed. Baltimore: Lippincott Williams & Wilkins; 2009: 30-49.
20. Kayiran SM, Dindar A, Gurakan B. An evaluation of children with Kawasaki disease in Istanbul: a retrospective follow-up study Clinics (Sao Paulo) 2010; 65: 1261-5.
21. Gardner-Medwin JM, Dolezalova P, Cummins C, Southwood TR. Incidence of Henoch-Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet 2002; 360: 1197-202.
22. Saffar MJ, Reshidighader F. Kawasaki disease in East Mazanda¬ran Islamic Republic of Iran, 1997-2002. Eastern Mediterranean Health Journal 2005; 11: 28–35.
23. Emami Moghadam A. Hosseinzadeh NM. Study of Clinical and Laboratory Findings in Children with Kawasaki Disease Hospitalized at Ahvaz Abuzar and Golestan Hospitals. Jundishapur Scientific Medical Journal 2011; 9: 543-51.
24. Pierre R, Sue-Ho R, Watson D. Kawasaki syndrome in Jamaica. Pe¬diatr Infect Dis J 2000; 19: 539–43.
25. Du ZD, Zhang T, Liang L, Meng X, Li T, Kawasaki T, et al. Epidemio¬logic picture of Kawasaki disease in Beijing from 1995 through 1999. Pediatr Infect Dis
J 2002; 21: 103–7.
26. Park YW, Han JW, Park IS, Kim CH, Cha SH, Ma JS, et al. Kawasaki disease in Korea, 2003-2005. Pediatr Infect Dis J 2007; 26: 821–3.
27. Gorczyca D, Postępski J, Olesińska E, Lubieniecka M, Lachór-Motyka I, Opoka-Winiarska V, Gruenpeter A. The clinical profile of Kawasaki disease of children from three Polishcenters: a retrospective study.
Rheumatol Int 2014; 34: 875-80.
28. Moradinezhad MH, Kiani A. Kawasaki Disease in 159 Iranian Children. IRANIAN journal of pediatrics 2007; 17: 241-6.
29. Lee BW, Tay JS, Yip WC, Yap HK, Chan KY, Low PS. Kawasaki syn¬drome in Chinese children. Ann Trop Paediatr 1989; 9: 147–51.
30. Schiller B, Fasth A, Bjorkhem G, Elinder G. Kawasaki disease in Sweden: incidence and clinical features. Acta Paediatr 1995; 84: 769–74.
31. Sadeghi P, Izadi A, Mojtahedi SY, Khedmat L, Jafari M, Afshin A, et al. A 10-year cross-sectional retrospective study on Kawasaki disease in Iranian children: incidence, clinical manifestations, complications, and treatment patterns. BMC Infect Dis 2021; 21: 368.
32. Burns JC, Cayan DR, Tong G, Bainto EV. Turner CL, Shike H, et al. Seasonality and Temporal Clustering of Kawasaki Syndrome. Epidemiology 2005 16: 220–5.
33. Chang RK. Hospitalizations for Kawasaki disease among chil¬dren in the United States, 1988-1997. Pediatrics 2002; 109: e87.
34. Clausen H, Howarth C, Giardini A. Kawasaki disease: always straight to the heart? BMJ Case Rep 2012; 2012: bcr2012006505.
35. Rowley AH, Shulman ST. New developments in the search for the etiologic agent of Kawasaki disease. Curr Opin Pediatr 2007; 19: 71-4.
36. Bal AK, Prasad D, Umali Pamintuan MA, Mammen-Prasad E, Petrova A. Timing of intravenous immunoglobulin treatment and risk of coronary artery abnormalities in children with Kawasaki disease. Pediatr Neonatol 2014; 55: 387-92.
37. Brien JA. Ototoxicity associated with salicylates: a brief review. Drug Saf 1993; 9: 143-8.
38. Shulman ST, Rowley AH. Advances in Kawasaki disease. Eur J Pediatr 2004; 163: 285-91.
39. Day RO, Graham GG, Bieri D, Brown M, Cairns D, Harris G, et al. Concentration-response relationships for salicylate-induced ototoxicity in normal volunteers. Br J Clin Pharmacol 1989; 28: 695-702.
| Files | ||
| Issue | Vol 15, No 4 (December 2021) | |
| Section | Original Articles | |
| DOI | https://doi.org/10.18502/jfrh.v15i4.7890 | |
| Keywords | ||
| Mucocutaneous Lymph Node Syndrome Aspirin Immunoglobulins Coronary Artery Disease Hearing disorders | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Karimi Yazdi A, Akbariasbagh P, Aghighi Y, Raeeskarami SR, Toomaj K, Heidari S, Alamdari S, Sahebi L. Impact of Early Treatment with High-Dose Intravenous Immunoglobulin on Incidence of Kawasaki Disease Complications in Iranian Children. J Family Reprod Health. 2021;15(4):242-247.
